A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Clinical trial NCT02927769 · COMPLETED

Trial details

NCT number: NCT02927769
Sponsor: Bristol-Myers Squibb
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hodgkin Disease

Start date: 2017-03-28
Primary completion: 2024-05-28
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.